These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 1663929)

  • 21. Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria.
    Goldstein EJ; Citron DM
    Antimicrob Agents Chemother; 1992 May; 36(5):1158-62. PubMed ID: 1324640
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activity of temafloxacin and other fluoroquinolones against typical and atypical community-acquired respiratory tract pathogens.
    Hardy DJ
    Am J Med; 1991 Dec; 91(6A):12S-14S. PubMed ID: 1662881
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interpretive criteria and quality control parameters for testing susceptibility of Haemophilus influenzae to enoxacin, ofloxacin, and temafloxacin.
    Barry AL; Jorgensen JH; Hardy DJ; Allen SD; Baker CN; Fuchs PC; McLaughlin JC
    J Clin Microbiol; 1992 Nov; 30(11):3013-5. PubMed ID: 1333487
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activity of CP-74667 compared with four other fluoroquinolones.
    Jones RN; Erwin ME
    Diagn Microbiol Infect Dis; 1992 Aug; 15(6):531-6. PubMed ID: 1330419
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differing activities of quinolones against ciprofloxacin-susceptible and ciprofloxacin-resistant, methicillin-resistant Staphylococcus aureus.
    Maple PA; Hamilton-Miller JM; Brumfitt W
    Antimicrob Agents Chemother; 1991 Feb; 35(2):345-50. PubMed ID: 1827242
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the bactericidal activity of temafloxacin.
    Jacobs MR
    Am J Med; 1991 Dec; 91(6A):31S-34S. PubMed ID: 1662893
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones.
    Montanari MP; Prenna M; Mingoia M; Ripa S; Varaldo PE
    Chemotherapy; 1998; 44(2):85-93. PubMed ID: 9551237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In-vitro activity of temafloxacin for gram-positive pathogens.
    Bille J; Glauser MP
    J Antimicrob Chemother; 1991 Dec; 28 Suppl C():9-14. PubMed ID: 1664835
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic effect of quinolones and oxacillin on methicillin-resistant Staphylococcus species.
    Rohner P; Herter C; Auckenthaler R; Pechère JC; Waldvogel FA; Lew DP
    Antimicrob Agents Chemother; 1989 Dec; 33(12):2037-41. PubMed ID: 2619272
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the bactericidal activities and post-antibiotic effects of the Des-F(6)-quinolone BMS-284756, levofloxacin, and ciprofloxacin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus.
    Ryan BM; Mazzucco CE; Lawrence LE; Ho H; Warr G; Barrett JF; Frosco M
    Eur J Clin Microbiol Infect Dis; 2002 Jan; 21(1):27-34. PubMed ID: 11913498
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of increasing levels of quinolone resistance on in-vitro activity of four quinolones.
    Thomson KS; Sanders CC
    J Antimicrob Chemother; 1998 Aug; 42(2):179-87. PubMed ID: 9738835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fluoroquinolone resistance among methicillin-resistant staphylococci after usage of fluoroquinolones other than ciprofloxacin in Taiwan.
    Chang SC; Hsieh WC; Luh KT
    Diagn Microbiol Infect Dis; 1994 Jul; 19(3):143-7. PubMed ID: 7820993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative antimicrobial activity of lomefloxacin, norfloxacin, ofloxacin, ciprofloxacin and enoxacin against > 500 bacterial isolates.
    Ismaeel NA; Tayeb OS
    Microbios; 1993; 74(300):147-54. PubMed ID: 8396196
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cross-resistance analysis for clinafloxacin compared with ciprofloxacin, fleroxacin, ofloxacin, and sparfloxacin using a predictor panel of ciprofloxacin-resistant bacteria.
    Cormican MG; Jones RN
    J Antimicrob Chemother; 1995 Aug; 36(2):431-4. PubMed ID: 8522474
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multicenter in vitro comparative study of fluoroquinolones against 25,129 gram-positive and gram-negative clinical isolates.
    Prosser BL; Beskid G
    Diagn Microbiol Infect Dis; 1995 Jan; 21(1):33-45. PubMed ID: 7789095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Spontaneously occurring staphylococcal mutants resistant to clinically achievable concentrations of ciprofloxacin and temafloxacin.
    Barry AL; Pfaller MA; Fuchs PC
    Eur J Clin Microbiol Infect Dis; 1992 Mar; 11(3):243-6. PubMed ID: 1317799
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro comparison of A-56619, A-56620, amifloxacin, ciprofloxacin, enoxacin, norfloxacin, and ofloxacin against methicillin-resistant Staphylococcus aureus.
    Smith SM
    Antimicrob Agents Chemother; 1986 Feb; 29(2):325-6. PubMed ID: 2940966
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin.
    Barry AL; Fuchs PC
    J Chemother; 1997 Feb; 9(1):9-16. PubMed ID: 9106012
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A multicenter study on the comparative in vitro activity of fleroxacin and three other quinolones: an interim report from 27 centers.
    Beskid G; Prosser BL
    Am J Med; 1993 Mar; 94(3A):2S-8S. PubMed ID: 8383919
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activity of levofloxacin against coagulase-positive and -negative staphylococci.
    Cafiso V; Messina C; Santagati M; Campanile F; Bonfiglio G; Stefani S
    Drugs Exp Clin Res; 2001; 27(3):107-11. PubMed ID: 11447768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.